AAV viral vector delivery to the brain by shape-conforming MR-guided infusions

Journal of Controlled Release

Volumn 240, Issue , 2016, Pages 434-442

  Bankiewicz, Krystof S ^a   Sudhakar, Vivek ^a   Samaranch, Lluis ^a   San Sebastian, Waldy ^a   Bringas, John ^a   Forsayeth, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adeno associated virus; Axonal transport; Brain delivery; Clinical trial; Gene therapy; MRI; Pre clinical research; Shape fitting

Indexed keywords

GENE EXPRESSION; GENE TRANSFER; GENES; MAGNETIC RESONANCE IMAGING; MEDICAL APPLICATIONS; VECTORS; VIRUSES;

ADENO-ASSOCIATED VIRUS; AXONAL TRANSPORTS; BRAIN DELIVERY; CLINICAL TRIAL; PRE-CLINICAL; SHAPE FITTING;

GENE THERAPY;

AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; NEUROTROPHIN; NEURTURIN; PARVOVIRUS VECTOR; TYROSINE 3 MONOOXYGENASE;

ARTICLE; BRAIN CELL; BRAIN REGION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; GENE THERAPY; GENETIC DISORDER; HUMAN; INFUSION SYSTEM; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; NERVE FIBER TRANSPORT; NEURONAVIGATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; THERMODYNAMICS; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; ADMINISTRATION AND DOSAGE; ANIMAL; BRAIN; DEPENDOPARVOVIRUS; DEVICES; DIAGNOSTIC IMAGING; EQUIPMENT DESIGN; GENE TRANSFER; GENE VECTOR; GENETICS; METABOLISM; PROCEDURES;

ANIMALS; BRAIN; CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; EQUIPMENT DESIGN; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE;

EID: 84959272376     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.02.034     Document Type: Article

References (64)

1. [1] Hadaczek, P., Eberling, J.L., Pivirotto, P., Bringas, J., Forsayeth, J., Bankiewicz, K.S., Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol. Ther. 18 (2010), 1458–1461.
2. [2] Forsayeth, J., Bankiewicz, K.S., Aminoff, M.J., Gene therapy for Parkinson's disease: where are we now and where are we going?. Expert Rev. Neurother. 10 (2010), 1839–1845.
3. [3] Richardson, R.M., Varenika, V., Forsayeth, J.R., Bankiewicz, K.S., Future applications: gene therapy. Neurosurg. Clin. N. Am. 20 (2009), 205–210.
4. [4] Kells, A.P., Hadaczek, P., Yin, D., Bringas, J., Varenika, V., Forsayeth, J., Bankiewicz, K.S., Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 2407–2411.
5. [5] Salegio, E.A., Samaranch, L., Kells, A.P., Mittermeyer, G., San Sebastian, W., Zhou, S., Beyer, J., Forsayeth, J., Bankiewicz, K.S., Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther., 2012.
6. [6] San Sebastian, W., Samaranch, L., Heller, G., Kells, A.P., Bringas, J., Pivirotto, P., Forsayeth, J., Bankiewicz, K.S., Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain. Gene Ther. 20 (2013), 1178–1183.
7. [7] Krauze, M.T., Saito, R., Noble, C., Tamas, M., Bringas, J., Park, J.W., Berger, M.S., Bankiewicz, K., Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J. Neurosurg. 103 (2005), 923–929.
8. [8] Varenika, V., Kells, A.P., Valles, F., Hadaczek, P., Forsayeth, J., Bankiewicz, K.S., Controlled dissemination of AAV vectors in the primate brain. Prog. Brain Res. 175 (2009), 163–172.
9. [9] Valles, F., Fiandaca, M.S., Bringas, J., Dickinson, P., LeCouteur, R., Higgins, R., Berger, M., Forsayeth, J., Bankiewicz, K.S., Anatomic compression caused by high-volume convection-enhanced delivery to the brain. Neurosurgery 65 (2009), 579–585 (discussion 585-576).
10. [10] Valles, F., Fiandaca, M.S., Eberling, J.L., Starr, P.A., Larson, P.S., Christine, C.W., Forsayeth, J., Richardson, R.M., Su, X., Aminoff, M.J., Bankiewicz, K.S., Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease. Neurosurgery 67 (2010), 1377–1385.
11. [11] Varenika, V., Dickenson, P., Bringas, J., LeCouteur, R., Higgins, R., Park, J.W., Fiandaca, M., Berger, M.S., Sampson, J.H., Bankiewicz, K.S., Real-time imaging of CED in the brain permits detection of infusate leakage. J. Neurosurg. 109 (2008), 874–880.
12. [12] Richardson, R.M., Gimenez, F., Salegio, E.A., Su, X., Bringas, J., Berger, M.S., Bankiewicz, K.S., T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery. Neurosurgery 69 (2011), 154–163 (discussion 163).
13. [13] Richardson, R.M., Kells, A.P., Martin, A.J., Larson, P.S., Starr, P.A., Piferi, P.G., Bates, G., Tansey, L., Rosenbluth, K.H., Bringas, J.R., Berger, M.S., Bankiewicz, K.S., Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact. Funct. Neurosurg. 89 (2011), 141–151.
14. [14] Richardson, R.M., Kells, A.P., Rosenbluth, K.H., Salegio, E.A., Fiandaca, M.S., Larson, P.S., Starr, P.A., Martin, A.J., Lonser, R.R., Federoff, H.J., Forsayeth, J.R., Bankiewicz, K.S., Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol. Ther. 19 (2011), 1048–1057.
15. [15] Rosenbluth, K.H., Eschermann, J.F., Mittermeyer, G., Thomson, R., Mittermeyer, S., Bankiewicz, K.S., Analysis of a simulation algorithm for direct brain drug delivery. Neuroimage 59 (2012), 2423–2429.
16. [16] Rosenbluth, K.H., Gimenez, F., Kells, A.P., Salegio, E.A., Mittermeyer, G.M., Modera, K., Kohal, A., Bankiewicz, K.S., Automated segmentation tool for brain infusions. PLoS One, 8, 2013, e64452.
17. [17] Bartus, R.T., Herzog, C.D., Chu, Y., Wilson, A., Brown, L., Siffert, J., Johnson, E.M. Jr., Olanow, C.W., Mufson, E.J., Kordower, J.H., Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov. Disord. 26 (2011), 27–36.
18. [18] Eberling, J.L., Jagust, W.J., Christine, C.W., Starr, P., Larson, P., Bankiewicz, K.S., Aminoff, M.J., Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70 (2008), 1980–1983.
19. [19] Marks, W.J. Jr., Bartus, R.T., Siffert, J., Davis, C.S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., Bakay, R., Watts, R., Guthrie, B., Jankovic, J., Simpson, R., Tagliati, M., Alterman, R., Stern, M., Baltuch, G., Starr, P.A., Larson, P.S., Ostrem, J.L., Nutt, J., Kieburtz, K., Kordower, J.H., Olanow, C.W., Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 9 (2010), 1164–1172.
20. [20] Bobo, R.H., Laske, D.W., Akbasak, A., Morrison, P.F., Dedrick, R.L., Oldfield, E.H., Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 2076–2080.
21. [21] Hadaczek, P., Yamashita, Y., Mirek, H., Tamas, L., Bohn, M.C., Noble, C., Park, J.W., Bankiewicz, K., The “perivascular pump” driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol. Ther. 14 (2006), 69–78.
22. [22] Gill, S.S., Patel, N.K., Hotton, G.R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D.J., Svendsen, C.N., Heywood, P., Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9 (2003), 589–595.
23. [23] Fiandaca, M.S., Forsayeth, J.R., Dickinson, P.J., Bankiewicz, K.S., Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 5 (2008), 123–127.
24. [24] Fiandaca, M.S., Varenika, V., Eberling, J., McKnight, T., Bringas, J., Pivirotto, P., Beyer, J., Hadaczek, P., Bowers, W., Park, J., Federoff, H., Forsayeth, J., Bankiewicz, K.S., Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage 47:Suppl. 2 (2009), T27–T35.
25. [25] Lonser, R.R., Warren, K.E., Butman, J.A., Quezado, Z., Robison, R.A., Walbridge, S., Schiffman, R., Merrill, M., Walker, M.L., Park, D.M., Croteau, D., Brady, R.O., Oldfield, E.H., Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J. Neurosurg. 107 (2007), 190–197.
26. [26] Su, X., Kells, A.P., Salegio, E.A., Richardson, R.M., Hadaczek, P., Beyer, J., Bringas, J., Pivirotto, P., Forsayeth, J., Bankiewicz, K.S., Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors. Mol. Ther. 18 (2010), 1490–1495.
27. [27] Yin, D., Richardson, R.M., Fiandaca, M.S., Bringas, J., Forsayeth, J., Berger, M.S., Bankiewicz, K.S., Cannula placement for effective convection-enhanced delivery in the non-human primate thalamus and brainstem: implications for clinical delivery of therapeutics. J. Neurosurg. 113 (2010), 240–248.
28. [28] Yin, D., Valles, F.E., Fiandaca, M.S., Bringas, J., Gimenez, F., Berger, M.S., Forsayeth, J., Bankiewicz, K.S., Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage 187 (2009), 46–51.
29. [29] Starr, P.A., Martin, A.J., Larson, P.S., Implantation of deep brain stimulator electrodes using interventional MRI. Neurosurg. Clin. N. Am. 20 (2009), 193–203.
30. [30] Martin, A.J., Larson, P.S., Ostrem, J.L., Starr, P.A., Interventional magnetic resonance guidance of deep brain stimulator implantation for Parkinson disease. Top. Magn. Reson. Imaging 19 (2009), 213–221.
31. [31] Yin, D., Valles, F.E., Fiandaca, M.S., Forsayeth, J., Larson, P., Starr, P., Bankiewicz, K.S., Striatal volume differences between non-human and human primates. J. Neurosci. Methods 176 (2009), 200–205.
32. [32] Breeze, R.E., Wells, T.H. Jr., Freed, C.R., Implantation of fetal tissue for the management of Parkinson's disease: a technical note. Neurosurgery 36 (1995), 1044–1047 (discussion 1047–1048).
33. [33] Forsayeth, J., Bankiewicz, K.S., Transduction of antigen-presenting cells in the brain by AAV9 warrants caution in preclinical studies. Mol. Ther., 23, 2015, 612.
34. [34] Ciesielska, A., Mittermeyer, G., Hadaczek, P., Kells, A.P., Forsayeth, J., Bankiewicz, K.S., Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol. Ther. 19 (2011), 922–927.
35. [35] Kells, A.P., Forsayeth, J., Bankiewicz, K.S., Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain. Neurobiol. Dis., 2011.
36. [36] Hadaczek, P., Mirek, H., Bringas, J., Cunningham, J., Bankiewicz, K., Basic fibroblast growth factor enhances transduction, distribution, and axonal transport of adeno-associated virus type 2 vector in rat brain. Hum. Gene Ther. 15 (2004), 469–479.
37. [37] Bankiewicz, K.S., Forsayeth, J., Eberling, J.L., Sanchez-Pernaute, R., Pivirotto, P., Bringas, J., Herscovitch, P., Carson, R.E., Eckelman, W., Reutter, B., Cunningham, J., Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol. Ther. 14 (2006), 564–570.
38. [38] Forsayeth, J.R., Eberling, J.L., Sanftner, L.M., Zhen, Z., Pivirotto, P., Bringas, J., Cunningham, J., Bankiewicz, K.S., A dose-ranging study of AAV-hAADC therapy in parkinsonian monkeys. Mol. Ther. 14 (2006), 571–577.
39. [39] Maller, A., Hyland, K., Milstien, S., Biaggioni, I., Butler, I.J., Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family. J. Child Neurol. 12 (1997), 349–354.
40. [40] Pons, R., Ford, B., Chiriboga, C.A., Clayton, P.T., Hinton, V., Hyland, K., Sharma, R., De Vivo, D.C., Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis. Neurology 62 (2004), 1058–1065.
41. [41] Manegold, C., Hoffmann, G.F., Degen, I., Ikonomidou, H., Knust, A., Laass, M.W., Pritsch, M., Wilichowski, E., Horster, F., Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J. Inherit. Metab. Dis. 32 (2009), 371–380.
42. [42] Allen, G.F., Land, J.M., Heales, S.J., A new perspective on the treatment of aromatic L-amino acid decarboxylase deficiency. Mol. Genet. Metab. 97 (2009), 6–14.
43. [43] San Sebastian, W., Kells, A.P., Bringas, J., Samaranch, L., Hadaczek, P., Ciesielska, A., Macayan, M., Pivirotto, P.J., Forsayeth, J., Osborne, S., Wright, J.F., Green, F., Heller, G., Bankiewicz, K.S., Safety and tolerability of MRI-guided infusion of AAV2-hAADC into the mid-brain of non-human primate. Mol. Ther. Methods Clin. Dev., 3, 2014.
44. [44] Hwu, W.L., Muramatsu, S., Tseng, S.H., Tzen, K.Y., Lee, N.C., Chien, Y.H., Snyder, R.O., Byrne, B.J., Tai, C.H., Wu, R.M., Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci. Transl. Med., 4, 2012, 134ra161.
45. [45] Bergman, H., Wichmann, T., DeLong, M.R., Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249 (1990), 1436–1438.
46. [46] Hamani, C., Saint-Cyr, J.A., Fraser, J., Kaplitt, M., Lozano, A.M., The subthalamic nucleus in the context of movement disorders. Brain 127 (2004), 4–20.
47. [47] Luo, J., Kaplitt, M.G., Fitzsimons, H.L., Zuzga, D.S., Liu, Y., Oshinsky, M.L., During, M.J., Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298 (2002), 425–429.
48. [48] Emborg, M.E., Carbon, M., Holden, J.E., During, M.J., Ma, Y., Tang, C., Moirano, J., Fitzsimons, H., Roitberg, B.Z., Tuccar, E., Roberts, A., Kaplitt, M.G., Eidelberg, D., Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J. Cereb. Blood Flow Metab. 27 (2007), 501–509.
49. [49] Kaplitt, M.G., Feigin, A., Tang, C., Fitzsimons, H.L., Mattis, P., Lawlor, P.A., Bland, R.J., Young, D., Strybing, K., Eidelberg, D., During, M.J., Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369 (2007), 2097–2105.
50. [50] LeWitt, P.A., Rezai, A.R., Leehey, M.A., Ojemann, S.G., Flaherty, A.W., Eskandar, E.N., Kostyk, S.K., Thomas, K., Sarkar, A., Siddiqui, M.S., Tatter, S.B., Schwalb, J.M., Poston, K.L., Henderson, J.M., Kurlan, R.M., Richard, I.H., Van Meter, L., Sapan, C.V., During, M.J., Kaplitt, M.G., Feigin, A., AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 10 (2011), 309–319.
51. [51] Azzouz, M., Martin-Rendon, E., Barber, R.D., Mitrophanous, K.A., Carter, E.E., Rohll, J.B., Kingsman, S.M., Kingsman, A.J., Mazarakis, N.D., Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J. Neurosci. 22 (2002), 10302–10312.
52. [52] Jarraya, B., Boulet, S., Ralph, G.S., Jan, C., Bonvento, G., Azzouz, M., Miskin, J.E., Shin, M., Delzescaux, T., Drouot, X., Hérard, A.S., Day, D.M., Brouillet, E., Kingsman, S.M., Hantraye, P., Mitrophanous, K.A., Mazarakis, N.D., Palfi, S., Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci. Transl. Med., 1, 2009.
53. [53] Palfi, S., Gurruchaga, J.M., Ralph, G.S., Lepetit, H., Lavisse, S., Buttery, P.C., Watts, C., Miskin, J., Kelleher, M., Deeley, S., Iwamuro, H., Lefaucheur, J.P., Thiriez, C., Fenelon, G., Lucas, C., Brugières, P., Gabriel, I., Abhay, K., Drouot, X., Tani, N., Kas, A., Ghaleh, B., Le Corvoisier, P., Dolphin, P., Breen, D.P., Mason, S., Guzman, N.V., Mazarakis, N.D., Radcliffe, P.A., Harrop, R., Kingsman, S.M., Rascol, O., Naylor, S., Barker, R.A., Hantraye, P., Remy, P., Cesaro, P., Mitrophanous, K.A., Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 383 (2014), 1138–1146.
54. [54] Kotzbauer, P.T., Lampe, P.A., Heuckeroth, R.O., Golden, J.P., Creedon, D.J., Johnson, E.M. Jr., Milbrandt, J., Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384 (1996), 467–470.
55. [55] Horger, B.A., Nishimura, M.C., Armanini, M.P., Wang, L.C., Poulsen, K.T., Rosenblad, C., Kirik, D., Moffat, B., Simmons, L., Johnson, E. Jr., Milbrandt, J., Rosenthal, A., Bjorklund, A., Vandlen, R.A., Hynes, M.A., Phillips, H.S., Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J. Neurosci. 18 (1998), 4929–4937.
56. [56] Herzog, C.D., Dass, B., Gasmi, M., Bakay, R., Stansell, J.E., Tuszynski, M., Bankiewicz, K., Chen, E.Y., Chu, Y., Bishop, K., Kordower, J.H., Bartus, R.T., Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol. Ther. 16 (2008), 1737–1744.
57. [57] Herzog, C.D., Brown, L., Gammon, D., Kruegel, B., Lin, R., Wilson, A., Bolton, A., Printz, M., Gasmi, M., Bishop, K.M., Kordower, J.H., Bartus, R.T., Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery 64 (2009), 602–612 (discussion 612–3).
58. [58] Marks, W.J. Jr., Ostrem, J.L., Verhagen, L., Starr, P.A., Larson, P.S., Bakay, R.A., Taylor, R., Cahn-Weiner, D.A., Stoessl, A.J., Olanow, C.W., Bartus, R.T., Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol. 7 (2008), 400–408.
59. [59] Olanow, W.C., Bartus, R.T., Baumann, T.L., Factor, S., Boulis, N., Stacy, M., Turner, D.A., Marks, W., Larson, P., Starr, P.A., Jankovic, J., Simpson, R., Watts, R., Guthrie, B., Poston, K., Henderson, J.M., Stern, M., Baltuch, G., Goetz, C.G., Herzog, C., Kordower, J.H., Alterman, R., Lozano, A.M., Lang, A.E., Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann. Neurol. 78 (2015), 248–257.
60. [60] Huddleston, D.E., Factor, S.A., Of monkeys and men: analysis of the phase 2 double-blind, sham-surgery controlled, randomized trial of AAV2-neurturin gene therapy for Parkinson's disease. Curr. Neurol. Neurosci. Rep. 11 (2011), 345–348.
61. [61] Bartus, R.T., Herzog, C.D., Chu, Y., Wilson, A., Brown, L., Siffert, J., Johnson, E.M. Jr., Olanow, C.W., Mufson, E.J., Kordower, J.H., Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov. Disord. 26 (2011), 27–36.
62. [62] Gimenez, F., Krauze, M.T., Valles, F., Hadaczek, P., Bringas, J., Sharma, N., Forsayeth, J., Bankiewicz, K.S., Image-guided convection-enhanced delivery of GDNF protein into monkey putamen. Neuroimage 54:Suppl.1 (2011), S189–S195.
63. [63] Johnston, L.C., Eberling, J., Pivirotto, P., Hadaczek, P., Federoff, H.J., Forsayeth, J., Bankiewicz, K.S., Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum. Gene Ther. 20 (2009), 497–510.
64. [64] Bartus, R.T., Kordower, J.H., Johnson, E.M. Jr., Brown, L., Kruegel, B.R., Chu, Y., Baumann, T.L., Lang, A.E., Olanow, C.W., Herzog, C.D., Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies. Neurobiol. Dis. 78 (2015), 162–171.